Apogee Therapeutics, Inc. APGE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashEquivalentsAtCarryingValue.
The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Apogee Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Apogee Therapeutics, Inc.'s cash & equivalents?
- Apogee Therapeutics, Inc. (APGE) reported cash & equivalents of $451.8M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Apogee Therapeutics, Inc.'s cash & equivalents increased by 322.6% year-over-year, from $106.92M to $451.8M.
- What is the long-term trend for Apogee Therapeutics, Inc.'s cash & equivalents?
- Over 3 years (2022 to 2025), Apogee Therapeutics, Inc.'s cash & equivalents has grown at a -4.7% compound annual growth rate (CAGR), from $151.89M to $131.55M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.